Martin Investment Management LLC Has $7.85 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Martin Investment Management LLC increased its stake in Thermo Fisher Scientific Inc. by 5.7%, owning a total of 15,767 shares valued at approximately $7.85 million.
• Significant institutional interest was noted, with firms like GAMMA Investing LLC increasing their holdings by over 60,000% in the first quarter, bringing their total shares to 2.41 million.
• Thermo Fisher Scientific's latest quarterly earnings surpassed expectations, reporting an EPS of $5.36 and revenue of $10.86 billion, as well as announcing a quarterly dividend of $0.43 per share.

Martin Investment Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,767 shares of the medical research company's stock after purchasing an additional 851 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.0% of Martin Investment Management LLC's investment portfolio, making the stock its 17th largest position. Martin Investment Management LLC's holdings in Thermo Fisher Scientific were worth $7,846,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TMO. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Port Capital LLC grew its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the last quarter. Clark Capital Management Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after acquiring an additional 23 shares during the period. Monograph Wealth Advisors LLC boosted its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after purchasing an additional 23 shares during the period. Finally, Intergy Private Wealth LLC grew its position in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after purchasing an additional 23 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on TMO shares. Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total transaction of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,591,606.96. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,896 shares of company stock valued at $8,593,838 over the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 3.4%

NYSE TMO traded up $16.4780 during trading on Friday, reaching $500.2380. 1,778,365 shares of the company's stock were exchanged, compared to its average volume of 2,406,376. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company's fifty day simple moving average is $443.02 and its 200-day simple moving average is $456.60. The firm has a market capitalization of $188.89 billion, a PE ratio of 28.93, a P/E/G ratio of 2.67 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm earned $5.37 earnings per share. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.